Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

The invention relates to a method for obtaining a composition based on conifer bark enriched in dihydroquercetin or in tannins, comprising the following steps: a) grinding dried shavings of bark from a conifer to obtain a ground particulate material of conifer bark, and b) selecting, from the ground particulate material obtained in step a), the fraction of particles: of smallest size representing at most 40% by weight, relative to the total weight of the ground particulate material obtained in step a), this fraction being enriched in tannins; or of largest size representing at most 50% by weight, relative to the total weight of the ground particulate material obtained in step a), this fraction being enriched in dihydroquercetin.

The present invention relates to a composition for the treatment of colon disorder comprising oil palm polyphenolics (OPP) and fibres extracted from the vegetation liquor generated during the milling and extraction of oil from the oil palm fruit administered to a patient in an effective concentration of 50 mg gallic acid equivalents (GAE). The present invention further relates to a method of treatment and prevention of colon disorders and maintenance of gut health.

The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

A composition having an extract of seed of Emblica officinalis. Methods of preparing extract of seed of Emblica officinalis. An amla seed blend composition having various ratios of extracts of seeds of Emblica officinalis. Nutraceutical or pharmaceutical methods for decreasing the total cholesterol, decreasing triglyceride, decreasing blood glucose level, enhancing HDL-C levels, increasing the HDL-C level to total cholesterol ratio, lowering LDL-C levels, decreasing the CRP level, decreasing the intima media thickening, reducing hair fall in mammals especially human beings. The extract of seed of Emblica officinalis, or the amla seed blend composition is more effective compared to extracts prepared from fruits of Emblica officinalis.

A method is provided, comprising steps: (a) harvesting Cannabis plant matter predetermined time; (b) grinding the Cannabis plant matter; (c) inserting the ground Cannabis plant mater into a mesh filter bag; (d) pressing the mesh filter bag via a hydraulic press at a first speed and a first pressure, wherein the ground Cannabis plant matter is separated into Cannabis pulp and Cannabis juice; and (e) collecting the Cannabis juice for consumption.

Biologically active extracts of one or more of Vigna sp., Terminalia sp. or Cocos nucifera and compositions containing one or more of the extracts for the maintenance and improvement of the health and/or appearance of the skin and/or an epidermal appendage.

A system for producing a blended extract of cannabinoids and terpenes, which extracts terpenes using supercritical CO2, and extracts a cannabinoid concentrate from the residual material using a cold ethanol flush followed by distillation; the CO2-extracted terpenes are then added back to the cannabinoid concentrate in a final blending step. Blending terpenes at the end of extraction may enhance the flavor and effectiveness of the cannabinoid concentrate. By separately extracting terpenes and cannabinoids, optimal processes and parameters may be used for each step. Blending may combine terpenes and cannabinoids in any desired ratio; for example, a terpene-to-cannabinoid ratio of approximately 1:10 may be used. The ethanol used in the cold ethanol extraction of cannabinoids may be recovered and reused for subsequent batches. Cannabinoid concentrates may be redistilled multiple times to enhance their concentration, followed by terpene blending.

The invention relates to water-soluble granules for preparing a drinkable solution, in particular for preventing or treating symptoms associated with mild to moderate chronic venous insufficiency of the lower extremities, containing at least 20 per cent by weight of a concentrated extract of red wine leaves, and to a ready-to-use packaging unit comprising one or more portion sachets which contain the granules according to the invention.

The present disclosure relates to polygalacturonan rhamnogalacturonan (PGRG1) compositions, as well as methods of making and methods of using said compositions in medicinally useful and pharmaceutically useful forms. Specifically, the present disclosure provides purified PGRG1 compositions isolated from roots of the Astragalus genus of plants, and more particularly from the species Astragalus membranaceus, as well as PGRG1 compositions having a weight average molecular weight of at least 40 kiloDaltons (kDa).